Xiangyi Jiang

Dr. Xiangyi Jiang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2019 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
XJXiangyi Jiang
Xiangyi Jiang
XHXia Hao
Xia Hao
LJLanlan Jing
Lanlan Jing
GWGaochan Wu
Gaochan Wu
DKDongwei Kang
Dongwei Kang
Peng ZhanPeng Zhan
Peng Zhan
Introduction: Click chemistry has been exploited widely in the past to expedite lead discovery and optimization. Indeed, Copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry is a bioorthogonal reaction of widespread utility throughout medicinal chemistry and chemical biology. Areas covered: The authors review recent applications of CuAAC click chemistry to drug discovery based on the literature published since 2013. Furthermore, the authors provide the reader with their expert perspectives on the area including their outlook on future developments. Expert opinion: Click chemistry reactions are an important part of the medicinal chemistry toolbox and offer substantial advantages to medicinal chemists in terms of overcoming the limitations of useful chemical synthesis, increasing throughput, and improving the quality of compound libraries. To explore new chemical spaces for drug-like molecules containing a high degree of structural diversity, it may be useful to merge the diversity-oriented synthesis and ‘privileged’ substructure-based strategy with bioorthogonal reactions using sophisticated automation and flow systems to improve productivity. Large compound libraries obtained in this way should be of great value for the discovery of bioactive compounds and therapeutic agents.


17 February 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZWZhao Wang
Zhao Wang
SCSrinivasulu Cherukupalli
Srinivasulu Cherukupalli
MXMinghui Xie
Minghui Xie
WWWenbo Wang
Wenbo Wang
XJXiangyi Jiang
Xiangyi Jiang
XLXinyong Liu
Xinyong Liu

16 September 2019 in RSC Advances
Verified
Journal Article
Open access
PDF file
XJXiangyi Jiang
Xiangyi Jiang
GWGaochan Wu
Gaochan Wu
WZWaleed A. Zalloum
Waleed A. Zalloum
MMMegan Meuser
Megan Meuser
ADAlexej Dick
Alexej Dick
Peng ZhanPeng Zhan
Peng Zhan
The HIV-1 capsid (CA) protein plays crucial roles in both early and late stages of the viral life cycle, which has intrigued researchers to target it to develop anti-HIV drugs. Accordingly, in this research, we report the design, synthesis and biological evaluation of a series of novel phenylalanine derivatives as HIV-1 CA protein inhibitors using the Cu(I)-catalyzed azide and alkyne 1,3-dipolar cycloaddition (CuAAC) reaction. Among this series of inhibitors, compound II-10c displayed a remarkable anti-HIV activity (EC50 = 2.13 μM, CC50 > 35.49 μM). Furthermore, surface plasmon resonance (SPR) binding assays showed that compounds II-10c and PF-74 (lead compound) have similar affinities to HIV-1 CA monomer. Further investigation showed that the weak permeability and water solubility of representative compounds were probably the important factors that restricted their cell-based activity. Preliminary structure–activity relationships (SARs) were inferred based on the activities of these compounds, and their known structure. The most promising new compound was studied with molecular dynamics simulation (MD) to determine the preferred interactions with the drug target. Finally, the activities of members of this series of inhibitors were deeply inspected to find the potential reasons for their anti-HIV-1 activity from various perspectives. This highlights the important factors required to design compounds with improved potency.

19 April 2019 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
XJXiangyi Jiang
Xiangyi Jiang
JYJi Yu
Ji Yu
ZZZhongxia Zhou
Zhongxia Zhou
JKJacob Kongsted
Jacob Kongsted
YSYuning Song
Yuning Song
Peng ZhanPeng Zhan
Peng Zhan

1 May 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DKDongwei Kang
Dongwei Kang
DFDa Feng
Da Feng
LJLanlan Jing
Lanlan Jing
YSYanying Sun
Yanying Sun
FWFenju Wei
Fenju Wei
XLXinyong Liu
Xinyong Liu